Literature DB >> 17178848

Activated checkpoint kinase 2 provides a survival signal for tumor cells.

Jagadish C Ghosh1, Takehiko Dohi, Christopher M Raskett, Timothy F Kowalik, Dario C Altieri.   

Abstract

Tumor cells often become resistant to DNA damage-based therapy; however, the underlying mechanisms are not yet understood. Here, we show that tumor cells exposed to DNA damage counteract cell death by releasing the antiapoptotic protein, survivin, from mitochondria. This is independent of p53, and requires activated checkpoint kinase 2 (Chk2), a putative tumor suppressor. Molecular or genetic targeting of Chk2 prevents the release of survivin from mitochondria, enhances DNA damage-induced tumor cell apoptosis, and inhibits the growth of resistant in vivo tumors. Therefore, activated Chk2 circumvents its own tumor-suppressive functions by promoting tumor cell survival. Inhibiting Chk2 in combination with DNA-damaging agents may provide a rational approach for treating resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178848     DOI: 10.1158/0008-5472.CAN-06-3095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

2.  Enhancing CHK1 inhibitor lethality in glioblastoma.

Authors:  Yong Tang; Yun Dai; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-04-01       Impact factor: 4.742

3.  Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation.

Authors:  F Ye; Z Yang; Y Liu; D Gong; T Ji; J Wang; B Xi; J Zhou; D Ma; Q Gao
Journal:  Cancer Gene Ther       Date:  2014-05-23       Impact factor: 5.987

4.  Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis.

Authors:  Connie W Lee; Christopher M Raskett; Igor Prudovsky; Dario C Altieri
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

5.  p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expression.

Authors:  Su-Hyeong Kim; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-18

6.  CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Authors:  G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

7.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Dynamic changes to survivin subcellular localization are initiated by DNA damage.

Authors:  Maritess Gay Asumen; Tochukwu V Ifeacho; Luke Cockerham; Christina Pfandl; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

9.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Authors:  Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino
Journal:  Cancer Res       Date:  2016-07-22       Impact factor: 12.701

10.  A functional Notch-survivin gene signature in basal breast cancer.

Authors:  Connie W Lee; Karl Simin; Qin Liu; Janet Plescia; Minakshi Guha; Ashraf Khan; Chung-Cheng Hsieh; Dario C Altieri
Journal:  Breast Cancer Res       Date:  2008-11-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.